Novartis AG's Fiscal Year is From January To December.
The item "Price-To-Cashflow-Ratio" stands at 11.43 as of 09/30/2025.
As of the end of Novartis AG's third quarter, the item "Price To Cashflow Ratio" stands at 11.43. This represents an increase of 0.67 percent compared to it's value at the end of it's second quarter .
Regarding the One-Year-Change of the series, the current value constitutes a decrease of -17.70 percent compared to the value the year prior.
The 1 year change in percent is -17.70.
The 3 year change in percent is 27.03.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Price To Cashflow Ratio | 905,699,262,464.00 |
![]() | Johnson & Johnson - Price To Cashflow Ratio | 486,508,953,600.00 |
![]() | AbbVie Inc - Price To Cashflow Ratio | 399,570,305,024.00 |
![]() | Roche Holding AG - Price To Cashflow Ratio | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Price To Cashflow Ratio | 280,205,508,085.11 |